INVO Fertility (IVF) Stock Price, News & Analysis

INVO Fertility, Inc. (Nasdaq: IVF) is a healthcare services fertility company in the healthcare sector with a focus on assisted reproductive technology ("ART"). According to its public disclosures, the company is dedicated to expanding access to ART care for patients in need by combining fertility clinic operations with a proprietary medical device-enabled treatment approach.

INVO Fertility’s principal commercial strategy centers on building, acquiring, and operating fertility clinics. These include branded "INVO Centers" that are dedicated primarily to offering the intravaginal culture ("IVC") procedure enabled by the company’s INVOcell® medical device, as well as U.S.-based, profitable in vitro fertilization ("IVF") clinics. The company reports that it has two operational INVO Centers in the United States and one IVF clinic, and it continues to pursue acquisitions of additional fertility clinics through its INVO Centers LLC subsidiary.

Business model and operating segments

Based on company descriptions in SEC filings and news releases, INVO Fertility operates a healthcare services model supported by medical device commercialization. Its activities include:

• Operating and managing fertility clinics, including INVO Centers and an acquired IVF clinic, such as Wisconsin Fertility Institute.
• Acquiring non-clinical assets of independent fertility clinics through INVO Centers LLC, with the intent to integrate them into its operating platform.
• Engaging in the sale and distribution of the INVOcell device and related technology to third-party owned and operated fertility clinics.

Earlier SEC filings also describe reporting segments that historically included a Clinics Services segment, an INVOcell Device segment related to manufacture and sales of the device, and a Therapeutics segment tied to an acquired subsidiary. More recent company communications emphasize a return to an exclusive focus on fertility operations and the fertility marketplace, with NAYA Therapeutics returning to private status and INVO Fertility retaining only a minority interest.

INVOcell device and intravaginal culture (IVC)

INVO Fertility highlights the INVOcell as a proprietary medical device that enables its IVC procedure. The company describes INVOcell as the first device to allow fertilization and early embryo development to take place in vivo within the woman’s body. This IVC procedure is positioned by the company as an ART option that provides patients with a more connected, intimate, and, in the company’s view, more affordable experience compared to other ART treatments.

Across multiple news releases and filings, INVO Fertility states that it believes the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and that it considers IVC to be significantly more effective than intrauterine insemination ("IUI"). The company also reports efforts to expand clinical and embryology training support and adjust pricing for INVOcell to encourage adoption by fertility clinics.

Clinic network and expansion strategy

INVO Fertility describes a multi-pronged strategy to build a network of fertility centers. This includes:

• Operating two INVO Centers in the United States and one IVF clinic.
• Pursuing acquisitions of additional clinics, such as the signed asset purchase agreement to acquire the non-clinical assets of Family Beginnings, P.C., a fertility clinic in Indianapolis, Indiana, through INVO Centers LLC, subject to customary closing conditions.
• Developing a pipeline of fertility clinics that, according to company statements, are interested in joining its platform.

In its public communications, the company associates this strategy with a goal of expanding its geographic footprint of fertility care centers and reaching more patients seeking advanced fertility treatment options. It also notes that some acquired or partner clinics offer a range of reproductive services, including IVF, IVC using INVOcell, IUI, third-party reproduction services, fertility preservation, advanced diagnostic testing, and patient education and support programs.

Technology and operational initiatives

INVO Fertility reports that it continues to invest in clinic operations and supporting technologies. Examples disclosed by the company include:

• Launching telehealth capabilities at its Wisconsin clinic to expand geographic reach and provide convenient access to fertility care.
• Adding Platelet-Rich Plasma (PRP) therapy to the services at the Wisconsin clinic as part of a broader fertility services offering.
• Partnering with Heidi Health to integrate an AI-powered scribe platform at Wisconsin Fertility Institute, aimed at automating clinical documentation and reducing administrative burden for clinicians.
• Receiving a notice of allowance on a new patent for a modified version of the INVOcell device, which the company states extends intellectual property protection based on design changes informed by feedback from embryologists.

These initiatives are presented by the company as part of its effort to support patient-centered clinical care while also advancing its fertility technology platform.

Capital markets and corporate structure

INVO Fertility is incorporated in Nevada and lists its common stock on the Nasdaq Capital Market under the ticker symbol IVF, as reflected in SEC registration statements and company news releases. The company has engaged in various capital-raising activities, including private placements of common stock and warrants, issuances of preferred stock, and registration statements on Form S-1 to register shares for resale by existing security holders.

Recent filings describe actions such as a 1-for-8 reverse stock split effective November 28, 2025, adjustments to authorized shares of common stock proposed via proxy materials, and the use of Series C-2 Non-Voting Convertible Preferred Stock and warrants in financing transactions. These disclosures provide context for investors researching the IVF stock structure, potential dilution mechanisms, and capital resources.

Regulatory filings and governance

As a public company, INVO Fertility files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-Q, 10-K, 8-K, S-1, and proxy statements such as the Definitive Proxy Statement on Schedule 14A. These filings discuss matters such as:

• Financial results and adjusted EBITDA metrics.
• Auditor ratification proposals.
• Share authorization changes and stock incentive plan amendments.
• Material definitive agreements, including acquisition-related asset purchase agreements and settlement agreements.

Investors can use these documents to understand the company’s governance, capital structure, and key corporate actions over time.